Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival

Annals of Hematology

Volumn 89, Issue 1, 2010, Pages 25-33

  Labidi, Sana Intidhar ^a   Ménétrier Caux, Christine ^a   Chabaud, Sylvie ^a   Chassagne, Catherine ^a   Sebban, Catherine ^a   Gargi, Thérèse ^a   Biron, Pierre ^a   Blay, Jean Yves ^a   Ghesquières, Hervé ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Cytokine; Follicular lymphoma; Prognosis; TGF ; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 6; INTERLEUKIN 7; LACTATE DEHYDROGENASE; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 71349085560     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0777-8     Document Type: Article

References (37)

1. JO Armitage DD Weinsenburger 1998 New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project J Clin Oncol 16 2780 2795 1:STN:280:DyaK1czmvVChuw%3D%3D 9704731
2. SJ Horning 1993 Natural history of and therapy for the indolent non-Hodgkin's lymphomas Semin Oncol 20 75 88 1:STN:280:DyaK2c%2FisVSnsg%3D%3D 8211209
3. Q Liu L Fayad F Cabanillas FB Hagemeister GD Ayers M Hess, et al. 2006 Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center J Clin Oncol 24 1582 1589 10.1200/JCO.2005.03.3696 16575009 (Pubitemid 46638782)
4. Coiffier B, Brice P, Delarue R, Haioun C, Souleau B, Mounier N et al (2007) Effect of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma. Blood (ASH annual meeting abstracts) 110, Abstract 386
5. P Solal-Celigny P Roy P Colombat J White JO Armitage R Arranz-Saez, et al. 2004 Follicular lymphoma international prognostic index Blood 104 1258 1265 10.1182/blood-2003-12-4434 1:CAS:528:DC%2BD2cXnt1ekuro%3D 15126323 (Pubitemid 39166497)
6. GA Salles 2007 Clinical features, prognosis and treatment of follicular lymphoma Hematology 2007 216 225 10.1182/asheducation-2007.1.216
7. D De Jong 2005 Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors J Clin Oncol 23 6358 6363 10.1200/JCO.2005.26.856 16155020 (Pubitemid 46218847)
8. SS Dave G Wright B Tan A Rosenwald RD Gascoyne WC Chan, et al. 2004 Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells N Engl J Med 351 2159 2169 10.1056/NEJMoa041869 1:CAS:528:DC%2BD2cXhtVSqtL%2FP 15548776 (Pubitemid 39507628)
9. J Carreras A Lopez-Guillermo BC Fox L Colomo A Martinez G Roncador, et al. 2006 High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma Blood 108 2957 2964 10.1182/blood-2006-04-018218 1:CAS:528:DC%2BD28XhtFygtrvK 16825494 (Pubitemid 44776932)
10. AM Lee AJ Clear M Calaminici AJ Davies S Jordan F MacDougall, et al. 2006 Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome J Clin Oncol 24 5052 5059 10.1200/JCO.2006.06.4642 1:CAS:528:DC%2BD28Xht1Gnur3N 17033038 (Pubitemid 46631409)
11. P Farinha H Masoudi BF Skinnider K Shumansky JJ Spinelli K Gill, et al. 2005 Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL) Blood 106 2169 2174 10.1182/blood-2005-04-1565 1:CAS:528:DC%2BD2MXhtVWksLjM 15933054 (Pubitemid 41291735)
12. D Canioni G Salles N Mounier N Brousse M Keuppens F Morchhauser, et al. 2008 High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial J Clin Oncol 26 440 446 10.1200/JCO.2007.12.8298 1:CAS:528:DC%2BD1cXitVGnurw%3D 18086798 (Pubitemid 351171697)
13. RO Casanovas N Mounier P Brice M Divine F Morschhauser J Gabarre, et al. 2007 Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 25 1732 1740 10.1200/JCO.2006.08.1331 (Pubitemid 46797954)
14. JY Blay N Burdin F Rousset G Lenoir P Biron T Philip, et al. 1993 Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor Blood 82 2169 2174 1:STN:280:DyaK2c%2Fgtlaksg%3D%3D 8400266
15. LM Pedersen TW Klausen UH Davidsen HE Johnsen 2005 Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma Ann Hematol 84 510 516 10.1007/s00277-005- 1020-x 1:CAS:528:DC%2BD2MXlvVynsbo%3D 15834569 (Pubitemid 41001461)
16. P Salven A Orpana L Teerenhovi H Joensuu 2000 Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients Blood 96 3712 3718 1:CAS:528: DC%2BD3cXosVGnt7c%3D 11090051
17. L Fayad F Cabanillas M Talpaz P McLaughlin R Kuzrock 1998 High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma Leuk Lymphoma 30 563 571 1:STN:280:DyaK1cznsFOgtA%3D%3D 9711918
18. Ansell SM, Novak AJ, Ziesmer S, LaPlant B, Cerhan JR, Yang ZZ et al (1997) Serum cytokine levels predict time to progression after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 110, abstract 3410
19. PP Carbone HS Kaplan K Musshoff DW Smithers M Tubiana 1971 Report of the committee on Hodgkin's disease staging classification Cancer Res 31 1860 1861 1:STN:280:DyaE38%2Fks1yitw%3D%3D 5121694
20. DA Vignali 2000 Multiplexed particle-based flow cytometric assays J Immunol Methods 243 243 255 10.1016/S0022-1759(00)00238-6 1:CAS:528: DC%2BD3cXmtlGksr8%3D 10986418 (Pubitemid 30734605)
21. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
22. Therneau T, Grambsch P (2000) Modeling survival data: extending the Cox model. Springer, New York
23. JR Cerhan S Wang MJ Maurer SM Ansell SM Geyer W Cozen, et al. 2007 Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival Blood 109 5439 5446 10.1182/blood-2006-11-058040 1:CAS:528: DC%2BD2sXmslOrtr8%3D 17327408 (Pubitemid 46890567)
24. VP Khatri MA Caligiuri 1998 A review of the association between interleukin-10 and human B-cell malignancies Cancer Immunol Immunother 46 239 244 10.1007/s002620050483 1:CAS:528:DyaK1cXmt1ertL8%3D 9690451 (Pubitemid 28332921)
25. Y Levy JC Brouet 1994 Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein J Clin Invest 93 424 428 10.1172/JCI116977 1:CAS:528:DyaK2cXitFGjsbo%3D 8282815
26. E Lech-Maranda L Baseggio J Bienvenu C Charlot F Berger D Rigal, et al. 2004 Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma Blood 103 3529 3534 10.1182/blood-2003-06-1850 1:CAS:528:DC%2BD2cXjslKgtLw%3D 14701701 (Pubitemid 38525688)
27. R Masood Y Zhang MW Bond DT Scadden T Moudgil RE Law, et al. 1995 Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma Blood 85 3423 3430 1:CAS:528:DyaK2MXmtlOmtrc%3D 7780129
28. DA Lebman JS Edmiston 1999 The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes Microbes Infect 1 1297 1304 10.1016/S1286-4579(99)00254-3 1:CAS:528:DC%2BD3cXjtFehsb0%3D 10611758 (Pubitemid 30020325)
29. P Golstein AH Wyllie 2001 T cell death and transforming growth factor beta1 J Exp Med 194 F19 F22 10.1084/jem.194.4.F19 1:CAS:528:DC%2BD3MXmt1egtb4%3D 11514612
30. D Tvrdik P Dundr G Povysil R Pytlik M Plankova 2006 Up-regulation of p21WAF1 expression is mediated by Sp1/Sp3 transcription factors in TGFbeta1-arrested malignant B cells Med Sci Monit 12 BR227 BR234 1:CAS:528:DC%2BD28XotlSrtLw%3D 16810128
31. D Tvrdik 2004 The effect of TGFbeta1 on the expression and phosphorylation of key cell-cycle regulators in malignant B cells Med Sci Monit 10 BR447 BR454 1:CAS:528:DC%2BD2MXls1CksA%3D%3D 15567975
32. H Husson EG Carideo D Neuberg J Schultze A Munoz PW Marks, et al. 2002 Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays Blood 99 282 289 10.1182/blood.V99.1.282 1:CAS:528:DC%2BD38XivF2gtg%3D%3D 11756183 (Pubitemid 34532995)
33. Huse K, Bakkebo M, Oksvold M, Smeland EB, Myklebust JH (2007) B cell lymphomas escape bone morphogenetic protein (BMP) induced growth inhibition: downregulation of BMP receptors and upregulation of inhibitory Smads. Blood (American Society of Hematology) 110, Abstract 2605
34. K Ganjoo 2007 Antiangiogenesis: a new approach to the treatment of lymphoma Leuk Lymphoma 48 454 455 10.1080/10428190701200059 17454583 (Pubitemid 46487750)
35. JM Jorgensen FB Sorensen K Bendix JL Nielsen ML Olsen AM Funder, et al. 2007 Angiogenesis in Non-Hodgkin Lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes Leuk Lymphoma 48 584 595 10.1080/10428190601083241 1:STN:280:DC%2BD2s3ksFentg%3D%3D 17454603 (Pubitemid 46487768)
36. Stopeck AT, Bellamy W, Unger J, Rimsza L, Lannone M, Fisher RI et al (2005) Phase II trial of single agent bevacizumab (Avastin) in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108. J Clin Oncol (ASCO Annual Meeting), Abstract 6592
37. Sorafenib in treating patients with recurrent diffuse large B-cell non-Hodgkin's lymphoma (2008) http://clinicaltrials.gov/ct2/show/record/ NCT00131937